Jump to any asset
849 assets, updated daily
As of September 15, 2026, Abbott Laboratories (ABT) trades at $103.09. CleaRank Financial AI rates it Buy with a fair value of $120.00, 16.4% above the current price. Wall Street's consensus target is $120.00 across 26 analysts. RSI at 17 is in oversold territory, and the price is below its 50-day average of $105.45.
Abbott Laboratories (ABT)
Abbott Laboratories NYSE
$103.09
1.140 (1.12%)
At close: Sep 14, 4:00 PM EDT
AI Analyst Consensus
74 / 100
Abbott Laboratories (ABT) is currently trading at $103.10, below its 50-day and 200-day moving averages ($105.45 and $105.72), signaling technical weakness. However, the company consistently beats earnings estimates, with the latest quarter to June 2026 showing a 2.34% EPS surprise and a 1.87% stock price increase. Wall Street analysts maintain a strong 'Buy' consensus with a median price target of $120, implying a 16.4% upside potential. The company's fundamental strength is underscored by its profit margin of 11.65% and a revenue growth rate of 13% year-over-year for the current year, exceeding the sector median of 8.1%. While insider activity shows net selling totaling $48.6 million versus $4.4 million in purchases, the overall analyst sentiment and forward-looking growth estimates suggest a positive outlook for the medical device giant.
ABT Price Analysis
Market Metrics
Open
$103.56
Day Range
$102.57 to $104.44
Prev Close
$101.95
Volume
7.79M
52-Week Range
$81.97 to $137.49
Market Cap
$178.39B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (5% difference), suggesting fair market pricing relative to industry standards.
ABT Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, ABT beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
ABT Analysis
Company's Health
4/5
12-Month Analyst Target
+16.40% Upside
Median of 26 analysts (12-month)
$120.00
AI Technical Analysis
Abbott Laboratories (ABT) is currently trading below its 50-day and 200-day moving averages ($105.45 and $105.72), indicating a bearish short-term trend. The Relative Strength Index (RSI) at 17.2 is in oversold territory, suggesting a potential for a bounce, though momentum indicators like MACD remain negative. Key support levels are being tested, with the current price of $103.10 near the low end of its trading range. Volume has been slightly below average, offering no strong conviction behind the current price action. The chart structure suggests that a sustained move above the 50-day SMA would be required to signal a shift in momentum.
ProTips
- Given the oversold RSI (17.2), consider monitoring for a technical bounce, but confirm with a move above the 50-day SMA ($105.45) before establishing a long position.
- While insider selling is notable, the strong analyst consensus and forward-looking growth estimates provide a supportive backdrop for the stock.
- As a major player in healthcare, Abbott Laboratories (ABT) is subject to regulatory changes; stay informed on any FDA or international health authority developments.
Key Catalysts
Bullish
Strong Analyst Buy Ratings and Price Targets
26 analysts cover ABT with a consensus 'Buy' rating and a median price target of $120, indicating significant upside potential from the current price.
Source: Wall Street AnalystsBullish
Consistent Earnings Beats
Abbott Laboratories has a history of meeting or exceeding EPS estimates, with the latest quarter showing a 2.34% surprise, suggesting resilient operational performance.
Source: Earnings ReportsBearish
Insider Net Selling Activity
Insiders have sold a net $48.6 million worth of stock, signaling a moderate sell signal and potentially indicating a lack of immediate conviction from management.
Source: Insider TransactionsBearish
Bearish Technical Indicators
The stock is trading below its 50-day and 200-day moving averages ($105.45 and $105.72), with a bearish RSI and MACD, suggesting downward price momentum.
Source: Technical AnalysisMarket Outlook
Abbott Laboratories (ABT) is expected to see continued growth, with Wall Street projecting revenue to reach $50.3 billion in the current year, a 13% increase year-over-year, and next year's revenue estimated at $54.6 billion with 9% growth. The company's strong profit margins and consistent earnings beats support a base case scenario where the stock could reach its median analyst target price of $120 within the next 6-12 months. Potential upside catalysts include further innovation in its medical device segments and successful expansion into new markets, which could drive growth beyond current estimates. Conversely, a failure to break its current technical downtrend, increased regulatory scrutiny, or unexpected competitive pressures could lead to a downside scenario, potentially testing the $76.92 level projected by long-range simulations.
Key Statistics
| Market Cap | 178.39B |
|---|---|
| P/E Ratio | 33.36 |
| EPS (TTM) | 3.09 |
| Dividend Yield | 2.41% |
| 52 Week High | 137.49 |
| 52 Week Low | 81.97 |
Abbott Laboratories (ABT) trades at a P/E ratio of 33.36, which is slightly above the sector median of 31.9, but its price-to-sales ratio of 3.83 is in line with the sector average. The company's return on equity stands at a healthy 10.58%, outperforming the sector median of 6.9%. With a profit margin of 11.65%, Abbott demonstrates strong profitability. Its debt-to-equity ratio of 0.63 is also within a reasonable range compared to the sector average. The current valuation appears justified by its strong profitability and growth prospects, especially considering the consistent earnings beats.
Earnings & Growth Analysis
Abbott Laboratories (ABT) has a strong track record of meeting or exceeding earnings expectations. In the most recent quarter to June 2026, EPS came in at $1.31, surpassing the estimate of $1.28 by 2.34% and leading to a 1.87% stock price increase. Prior quarters also show consistent performance, with EPS matching estimates or beating them, indicating reliable operational execution.
Key Risks
The primary risk for Abbott Laboratories (ABT) lies in its current technical weakness, trading below key moving averages and showing bearish momentum. Additionally, significant insider selling, with total sales of $48.6 million against $4.4 million in purchases, warrants attention, although the overall verdict is a moderate sell signal. Competition within the medical device sector remains intense, posing a continuous challenge to market share and pricing power.
Technical Indicators
| RSI (14) | 17.20 |
|---|---|
| MACD | -0.90 |
| SMA 50 | 105.45 |
| SMA 200 | 105.72 |
RSI
Oversold
SMA Cross
Neutral
Price vs SMA
Bearish
MACD
Bearish
Price is trading below the 50-day SMA, RSI at 17.2 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.11
Weak correlation
Nasdaq 100 (QQQ)
-0.03
Weak correlation
Bitcoin (BTC)
-0.03
Weak correlation
Gold (XAU)
+0.04
Weak correlation
Check Custom Correlation
How does any other asset move with ABT? One year of daily closes, Pearson correlation.
Try
ABT Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$101.03
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$103.09
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$97.69
MAX LOSS
-3.3%
Volatility-Adjusted Stop Loss
Calculated based on RSI (17.2) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$106.08
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$111.13
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$116.18
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for ABT is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 15, 2026.Growth of $10,000
A $10,000 investment in ABT in September 2016 would be worth about $25,071 today, compared with about $35,344 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ABT today could grow to about $22,473 by 2036 in the base case, with a bull case near $59,584 and a bear case around $8,476. Projections are statistical simulations, not guarantees.
ABT Stock Price Prediction: 2030
CleaRank's simulation projects a price near $143 for ABT by 2030 in the base case, from $103 today (1.4x over 4 years). The downside path ends near $76.92. These are outcomes of a Monte Carlo simulation run on ABT's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $82.12 | $112 | $152 |
| 2028 | $78.37 | $121 | $187 |
| 2029 | $77.05 | $131 | $224 |
| 2030 | $76.92 | $143 | $264 |
| 2031 | $77.55 | $155 | $308 |
| 2032 | $78.74 | $168 | $357 |
| 2033 | $80.37 | $182 | $411 |
| 2034 | $82.37 | $197 | $471 |
| 2035 | $84.72 | $214 | $539 |
| 2036 | $87.38 | $232 | $614 |
Method: 10,000 simulated price paths using ABT's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
ABT Insider Trading Analysis
Bought
$4.4M
5 Transactions
Sold
$48.6M
12 Transactions
Insiders
24
Active Traders
Avg Transaction
$3.1M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 25, 2026 | FORD ROBERT B.
Chief Executive Officer
|
Sell | 398.8K | $46.2M |
| Feb 5, 2025 | FORD ROBERT B.
Chief Executive Officer
|
Sell | 285.4K | $37.4M |
| Feb 1, 2021 | ALLEN HUBERT L.
Officer
|
Sell | 203.4K | $25.1M |
| Jan 30, 2025 | ALLEN HUBERT L.
Officer
|
Sell | 189.8K | $24.3M |
| Dec 13, 2021 | CAPEK JOHN M
Officer
|
Sell | 149.6K | $20.2M |
| Oct 21, 2024 | ALLEN HUBERT L.
Officer
|
Sell | 157.4K | $18.4M |
| Aug 27, 2021 | LANE ANDREW H
Executive Vice President
|
Sell | 135.9K | $17.1M |
| Sep 12, 2024 | FORD ROBERT B.
Chief Executive Officer
|
Sell | 141.7K | $16.5M |
| Mar 7, 2025 | EARNHARDT LISA D
President
|
Sell | 91.4K | $12.2M |
| Apr 30, 2021 | WATKIN JARED L
Officer
|
Sell | 94.6K | $11.3M |
Page 1 of 1
Frequently Asked Questions
What is Abbott Laboratories' stock forecast for 2030?
Abbott Laboratories' (ABT) stock forecast for 2030, based on Monte Carlo simulations, projects a base case price of $142.52, with a downside scenario of $76.92 and an upside scenario of $264.06. These are statistical outcomes, not guarantees.
Is Abbott Laboratories stock a buy right now?
Abbott Laboratories (ABT) is currently rated a 'Buy' by Wall Street analysts, with a consensus score of 74 out of 100. The median analyst price target of $120 suggests a potential upside of 16.4% from the current price of $103.10.
What are the key technical levels for Abbott Laboratories stock?
Abbott Laboratories (ABT) is currently trading below its 50-day SMA of $105.45 and its 200-day SMA of $105.72, indicating bearish short-term trends. The RSI is oversold at 17.2, suggesting a potential for a rebound, but confirmation requires a move back above these key moving averages.
How has Abbott Laboratories performed in recent earnings reports?
Abbott Laboratories (ABT) has consistently met or exceeded earnings expectations. The latest quarter to June 2026 saw EPS of $1.31 against an estimate of $1.28, a 2.34% surprise, and the stock reacted positively. Previous quarters also show a pattern of meeting or beating estimates.
What is the insider sentiment for Abbott Laboratories?
Insider sentiment for Abbott Laboratories (ABT) is currently a 'moderate sell signal,' with total insider sales of $48.6 million compared to total purchases of $4.4 million in recent filings. This indicates a net selling pressure from insiders.
How does Abbott Laboratories compare to its sector peers?
Abbott Laboratories (ABT) shows a higher P/E ratio (33.36) than the sector median (31.9) but offers a stronger return on equity (10.58% vs. 6.9%). Its revenue growth of 13% also surpasses the sector median of 8.1%, suggesting it is outperforming peers in growth despite a slightly higher valuation multiple.
What are the main risks facing Abbott Laboratories?
Key risks for Abbott Laboratories (ABT) include its current bearish technical trend, significant insider selling activity, and intense competition within the medical device industry. A sustained move below key support levels could exacerbate downward price pressure.